Norge -
norsk -
Statens legemiddelverk
zyprexa 5 mg
orifarm as - olanzapin - tablett, drasjert - 5 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 7.5 mg
farmagon - olanzapin - tablett, drasjert - 7.5 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
farmagon - olanzapin - tablett, drasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
cetraxal comp 3 mg/ ml / 0.25 mg/ ml
poa pharma scandinavia ab - ciprofloksacinhydroklorid / fluocinolonacetonid - Øredråper, oppløsning i endosebeholder - 3 mg/ ml / 0.25 mg/ ml
Norge -
norsk -
Statens legemiddelverk
ozalin 2 mg/ ml
primex pharmaceuticals oy - midazolam - mikstur, oppløsning i endosebeholder - 2 mg/ ml
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
orifarm as - olanzapin - pulver til injeksjonsvæske, oppløsning - 10 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
orifarm as - olanzapin - tablett, drasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
2care4 aps - olanzapin - tablett, drasjert - 10 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.